Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.88 |
| ▸ | ITK | Q08881 | 6/20 | 0.88 |
| ▸ | BTK | Q06187 | 8/20 | 0.83 |
| ▸ | JAK2 | O60674 | 1/20 | 0.83 |
| ▸ | LYN | P07948 | 1/20 | 0.83 |
| ▸ | TEC | P42680 | 1/20 | 0.83 |
| ▸ | TXK | P42681 | 1/20 | 0.83 |
| ▸ | BMX | P51813 | 1/20 | 0.83 |
| ▸ | JAK3 | P52333 | 1/20 | 0.83 |
| ▸ | CD69 | Q07108 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12519538 | 0.94 | EGFR (1.00) | EGFRITKBTKJAK2LYN | |
| SCHEMBL29722231 | 0.94 | EGFR (1.00) | EGFRITKBTKJAK2LYN | |
| SCHEMBL18737405 | 0.93 | EGFR (0.83) | EGFRITKBTKJAK2LYN | |
| SCHEMBL15828854 | 0.92 | EGFR (0.85) | EGFRITKBTKJAK2LYN | |
| SCHEMBL28441535 | 0.92 | EGFR (0.82) | EGFRITKBTKJAK2LYN | |
| Spebrutinib SCHEMBL626216 | 0.91 | EGFR (1.00) | EGFRITKBTKJAK2LYN | |
| Spebrutinib SCHEMBL29359972 | 0.91 | EGFR (1.00) | EGFRITKBTKJAK2LYN | |
| SCHEMBL28443383 | 0.91 | EGFR (0.81) | EGFRITKBTKJAK2LYN | |
| SCHEMBL29722399 | 0.91 | EGFR (1.00) | EGFRITKBTKJAK2LYN | |
| SCHEMBL12518308 | 0.91 | EGFR (1.00) | EGFRITKBTKJAK2LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-04-06 | — | — | US | disclosed |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-04-06 | — | — | US | disclosed |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-04-06 | — | — | US | disclosed |
| US-9549927-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549927-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549927-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9415049-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9415049-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9415049-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150374690-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2015-12-31 | — | — | US | disclosed |
| US-9126950-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126950-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140179720-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014100748-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100748-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179720-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179720-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374690-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ITK 2697/4885BTK 594/4885 |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ITK 2697/4885BTK 594/4885 |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ITK 2697/4885BTK 594/4885 |
| US-20140179720-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ITK 2697/4885BTK 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.